WO2023057819 - METHODS OF TREATING CANCER USING HSF1 PATHWAY INHIBITORS
National phase entry:
Publication Number
WO/2023/057819
Publication Date
13.04.2023
International Application No.
PCT/IB2022/000591
International Filing Date
06.10.2022
Title **
[English]
METHODS OF TREATING CANCER USING HSF1 PATHWAY INHIBITORS
[French]
MÉTHODES DE TRAITEMENT DU CANCER À L'AIDE D'INHIBITEURS DE LA VOIE HSF1
Applicants **
INSTITUTE OF CANCER RESEARCH
123 Old Brompton Road
London SW7 3RP, GB
Inventors
WORKMAN, Paul
Woodlands House, Arbinger Lane, Arbinger Common
Surrey RH5 6JF, GB
CLARK, Paul, Andrew
50a Munster Rd
London SW6 4EP, GB
TE POELE, Robert, Herman
36 Foxley Lane
Purley CR8 3EE, GB
Priority Data
63/252,657
06.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1359 | |
| EPO | Filing, Examination | 7593 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 3510 |
Total: 13632 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The disclosure is in part directed to a method of treating a cancer in a patient in need thereof, comprising administering to the patient an effective amount of a HSF1 pathway inhibitor, wherein the cancer comprises solid tumors identified as having an ARID 1 A mutation.[French]
La divulgation concerne en partie une méthode de traitement d'un cancer chez un patient le nécessitant, comprenant l'administration au patient d'une dose efficace d'un inhibiteur de la voie HSF1, le cancer comprenant des tumeurs solides chez lesquelles une mutation ARID 1 A a été identifiée.